The
global herpes treatment market size is
expected to grow by USD 677.02 million as per Technavio. This marks a
significant market growth compared to the 2019 growth estimates due to the
impact of the COVID-19 pandemic in the first half of 2020. Moreover, healthy growth
is expected to continue throughout the forecast period, and the market is
expected to grow at a CAGR of almost 4%.
Request Free Sample Report on COVID-19 Impacts
The market is driven by the increasing prevalence of herpes infection.
In addition, the rising prevalence rate of shingles in the older population is
anticipated to boost the growth of the herpes treatment market.
The increasing prevalence of herpes infection is expected to be one of
the key factors driving the herpes treatment market growth. Apart from
traditional risk factors such as sexual or physical contact with the infected
person, there have been several other factors contributing to the rising
prevalence of herpes. People with a weaker immune system due to the intake of
immunosuppressants for an organ transplant are vulnerable to herpes infection.
Also, people with medical conditions such as HIV or cancer patients undergoing
chemotherapy are at a higher risk of developing herpes. Thus, the increasing
prevalence of these medical conditions will lead to an increase in the
prevalence of herpes infection, thereby the driving market growth.
Buy 1 Technavio report and get the
second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before
purchasing
Major Five Herpes Treatment Companies:
Bausch Health Companies Inc.
Bausch Health Companies Inc. has business operations under various
segments, such as Bausch + Lomb/International, Salix, Ortho Dermatologics, and
Diversified Products. The company offers Zovirax (acyclovir) cream, which is a
herpes simplex virus (HSV) nucleoside analogue DNA polymerase inhibitor,
indicated for the treatment of recurrent herpes labialis in immunocompetent
adults and adolescents aged 12 and above.
Cipla Inc.
Cipla Inc. operates its business through two segments: pharmaceuticals
and new ventures. The company manufactures and offers generic Famvir for the
treatment of Herpes.
Eli Lilly and Co.
Eli Lilly and Co. offer products, such as neuroscience, endocrine,
anti-infectives, cardiovascular agents, and oncology. The company's key
offerings include Lovir 800 MG Tablet, which is an antiviral medication that
helps in treating viral infections like herpes labialis, herpes simplex,
shingles, genital herpes infection, and chickenpox.
Gilead Sciences Inc.
Gilead Sciences Inc. generates revenue through the discovery,
development, and commercialization of innovative medicines in areas of unmet
medical need. The company offers Vistide (cidofovir), which is an antiviral
drug used for the treatment of herpes simplex in patients with AIDS who do not
respond to acyclovir.
GlaxoSmithKline Plc
GlaxoSmithKline Plc has business operations under three segments:
pharmaceuticals, consumer healthcare, and vaccines. The company's key offerings
include Valtrex (valacyclovir), Zovirax (acyclovir), and Shingrix.
No comments:
Post a Comment